

6. Literatur

-

- [1] Collier, LH. Chlamydia. Topley and Wilson's Principles of Bacteriology, Virology and Immunity. 8th edition. Published Edward Arnold 1990; 629 - 646
- [2] www.chlamydiae.com/docs/Chlamydiales/'Chlamydialeshistory.htm, KDE & MEW, November 2002
- [3] Everett, KDE., Bush, RM & Andersen, AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. International Journal of Systemic and Evolutionary Microbiology 1999; 49:415-440
- [4] Popov VL, Shatkin AA, Pankratova VN, Smirnova NS, von Bonsdorff CH, Ekman MR, Morttinen A, Saikku P. Ultrastructure of Chlamydia pneumoniae in cell culture. FEMS Microbiol Lett 1991;15:68:129-34

- [5] Grayston JT, Wang SP, Kuo CC, Campbell LA. Current knowledge on *Chlamydia pneumoniae*, strain TWAR, an important cause of pneumonia and other acute respiratory diseases. *Eur J Clin Microbiol Infect Dis.* 1989;8(3):191–202
- [6] Everett KDE, Bush RM, Anderson AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for identification of organism. *Int. J Syst Bacteriol* 1999;49:425-440
- [7] Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP. A new respiratory tract pathogen: *Chlamydia pneumoniae* strain TWAR. *J Infect Dis.* 1990 Apr;161:618-25
- [8] Thom DH, Grayston JT, Campbell LA, Kuo CC, Diwan VK, Wang SP. Respiratory infection with *Chlamydia pneumoniae* in middle-aged and older adult outpatients. *Eur J Clin Microbiol Infect Dis.* 1994 Oct;13:785-92
- [9] Sessa R, Di Pietro M, Schiavoni G, Santino I, Benedetti-Valentini F, Perna R, Romano S, del Piano M. *Chlamydia pneumoniae* DNA in patients with symptomatic carotid atherosclerotic disease. *J Vasc Surg* 2003; 37:1027-1031

- [10] Sriram S, Ljunggren-Rose A, Yao SY, Whetsell WO Jr. Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis. *J Infect Dis.* 2005 Oct 1;192:1219-28
- [11] Ronchetti F, Ronchetti R, Guglielmi F, Chiappini I, Contini C, Filippo R, Santino I, Cerruto R, Bernardeschi D, Barbara M. Detection of Chlamydia pneumoniae in Cholesteatoma Tissue: Any Pathogenetic Role?. *Otology & Neurology* 2003 May 24:353-357
- [12] Falck G, Engstrand I, Gnarpe J, Gnarpe H. Association of Chlamydia pneumoniae with Otitis Media in Children. *Scand J Infect Dis*, 1998, 30:377-380
- [13] Hahn DL, Peeling RW, Dillon E, McDonald R, Saikku P. Serologic markers for Chlamydia pneumoniae in asthma. *Ann Allergy Asthma Immunol* 2000;84:227-233
- [14] Hahn, DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence?. *Ann Allergy Asthma Immunol* 1999;83:271-292
- [15] Hahn DL, McDonald R. Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma?: *Ann Allergs Asthma Immunol* 1998; 81:339-344
- [16] Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (Strain TWAR) Infection With Wheezing, Asthmatic Bronchitis, and Adult-Onset Asthma. *JAMA.*1991;266:225-230

- [17] [Rupp J, Koch M, van Zandbergen G](#), Solbach W, Brandt E, Maass M. Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model. FEMS Microbiol Lett. 2005;15:242:203-8
- [18] Suttorp, N. <http://www.charite.de/infektiologie/forschung/capnet.html>
- [19] Thalhammer F . Infektionen der unteren Atemwege. Aerztemagazin, Fortbildungsarbeit- 48/2002, www.aerztemagazin.at/
- [20] [Diaz FA, Labarca LJ, Perez CC](#) . Treatment of community-acquired pneumonia in adults. Rev Chilena Infectol. 2005;22 Suppl:s52-66
- [21] [Moreno BR, Riquelme OR](#). Etiology of community-acquired pneumonia in immunocompetent adults. Rev Chilena Infectol. 2005;22 Suppl:s18-25
- [22] [Stocks N, Turnidge J, Crockett A](#). Lower respiratory tract infections and community acquired pneumonia in adults. Aust Fam Physician. 2004;33(5):297-301
- [23] Baer G, Engelcke G, Abele Horn M, Schaad UB, Heininger U. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as Causative Agents of Community-Acquired Pneumoniae in Hospitalised Children and Adolescents. Eur J Clin Microbiol Infect Dis 2003;22:742-745

- [24] Macfarlane JT, Finch RG, Cotton RE: A colour atlas of respiratory infections. Chapman & Hall Medical, London 1993
- [25] [Sazawal S, Black RE: Pneumonia Case Management Trials Group](#). Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect Dis. 2003 Sep;3(9):547-56. Review.
- [26] Klig JE, Current challenges in lower respiratory infections in children. Curr Opin Pediatr 2004 ;16 :107-112
- [27] Hammerschlag MR, Pneumoniae due to Chlamydia pneumoniae in Children: Epidemiology, Diagnosis, and Treatment. Pediatric Pulmology 2003;36:384-390
- [28] Heiskanen-Kosma T, Korppi M, Laurila A, Jokinen C, Kleemola M, Saikku P. Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study. Scand J Infect Dis. 1999;31(3):255-9
- [29] Cosentini R, Esposito S, Blasi F, Clerici Schoeller M, Pinzani R, Tarsia P, Fagetti L, Arosio C, Principi N, Allegra L. Incidence of Chlamydia pneumoniae Infection in Vertically HIV-1 Infected Children. Eur J Clin Microbiol Infect Dis 1998;17:720-723
- [30] Baboonian C, Smith DA, Shapland D, Arno G, Zal B, Akiyu J, Kaski JC. Placental infection with Chlamydia pneumoniae and intrauterine growth

restriction. *Circulation* 2003;107:165-169

- [31] Marre R, Mertens T, Trautmann M, Vanek E (Hrsg): *Klinische Infektiologie*. Urban & Fischer Verlag, München, Jena, 2000, S.474
- [32] Laude G. Chlamydiosen (Teil 1):Erkrankungen durch *Chlamydia trachomatis*, Robert-Koch-Institut
www.rki.de/INFEKT/INFEKT.htm?/INFEKT/INF_A-Z/RATGEBER/RAT22.HTM&1
- [33] Eggert-Kruse W, Rohr G, Beck C et al. *Chlamydia trachomatis*-Infektionen und Fertilität. Robert-Koch-Institut,
www.rki.de/INFEKT/INFEPIFO/1972CHLA.htm
- [34] Smith KA, Bradley KK, Stobierski MG, Tengelsen LA, National Association of State Public Health Veterinarians Psittacosis Compendium Committee. Compendium of measures to control *Chlamydia psittaci* (formerly *Chlamydia psittaci*) infection among humans (psittacosis) and pet birds.
J Am Vet Med Assoc. 2005; 15:226(4):532-9
- [35] Junqueira LC, Carneiro J, *Histologie*, 1996, 4.Auflage, 453-462
- [36] Kelly RB. Microtubules, membrane traffic, and cell organization. *Cell.* 1990; 61:5-7

- [37] Gottlieb AI, Lowell Langille B, Wong MKK, Kim DW. Structure and function of endothelial cytoskeleton. *Lab Invest* 1991;65:123-136
- [38] Schnittler HJ, Wilke A, Gress T, Suttorp N, Drenckhahn D. Role of actin and myosin in the control of paracellular permeability in pig, rat and human vascular endothelium. *J Physiol*. 1990; 431: 379-401
- [39] Gruenberg J, Griffiths G, Howell KE. Characterization of the early endosome and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro. *J Cell Biol*. 1989; 108:1301-1316
- [40] Mukherjee , Gosh RN, Maxfield FR. Endocytosis. *Physiol Rev*. 1997; 77:759-803
- [41] Rose F, Kurth-Landwehr C, Sibelius K, Reuner H, Aktorius K, Seeger W, Grimminger F. Role of actin depolymerization in the surfactant secretory response of alveolar epithel type II cells. *Am J Respir Crit Care Med*. 1999; 159:206-212
- [42] Schramm N, Wyrick PB. Cytoskeletal requirements in Chlamydia trachomatis infection of host cells. *Infect Immun* 1995; 63:324-332
- [43] [Schurch S, Goerke J, Clements JA](#). Direct determination of surface tension in the lung. *Proc Natl Acad Sci USA*. 1976;73(12):4698-702
- [44] Clements JA, [Brown ES](#), [Johnson RP](#). Pulmonary surface tension and the mucus lining of the lungs: some theoretical considerations.. PMID: 13525272

- [45] Wright JR, Clements JA. Metabolism and turnover of lung surfactant. *Am Rev Resp Dis* 1987; 135: 426-444
- [46] Wright JR. Clearance and recycling of pulmonary surfactant. *Am J Physiol* 1990; 259: L1-L12
- [47] Hallman M, Epstein BL, Gluck L. Analysis of labeling and clearance of lung surfactant phospholipids in rabbit. Evidence of bidirectional surfactant flux between lamellar bodies and alveolar lavage. *J Clin Invest.* 1981;68(3):742-51
- [48] [Young SL, Fram EK, Larson E, Wright JR.](#) Recycling of surfactant lipid and apoprotein-A studied by electron microscopic autoradiography. *Am J Physiol.* 1993;265:L19-26
- [49] Honda Y, Tsunematsu K, Suzuki A, Akino T. Changes in phospholipids in bronchoalveolar lavage fluid of patients with interstitial lung diseases. *Lung.* 1988;166(5):293-301
- [50] [Pink DA.](#) Theoretical studies of phospholipid bilayers and monolayers. Perturbing probes, monolayer phase transitions, and computer simulations of lipid-protein bilayers. *Can J Biochem Cell Biol.* 1984;62(8):760-77

- [51] [Possmayer FA](#). Proposed nomenclature for pulmonary surfactant-associated proteins. *Am Rev Respir Dis*. 1988;138(4):990-8
- [52] Berg T, [Leth-Larsen R](#), [Holmskov U](#), Hojrup P. Structural characterisation of human proteinosis surfactant protein A., *Biochim Biophys Acta*. 2000;30:1543(1):159-73
- [53] Putman E, Creuwels LA, van Golde LM, Haagsman HP. Surface properties, morphology and protein composition of pulmonary surfactant subtypes. *Biochem J*. 1996;1:320(Pt 2): 599–605
- [54] [Wright JR](#), [Dobbs LG](#). Regulation of pulmonary surfactant secretion and clearance. *Annu Rev Physiol*. 1991;53:395-414
- [55] Wright JR. Immunoregulatory functions of surfactant proteins. *Nat Rev Immunol* 2005;5:58-68
- [56] [Jain D](#), [Dodia C](#), [Bates SR](#), [Hawgood S](#), [Poulain FR](#), [Fisher AB](#). SP-A is necessary for increased clearance of alveolar DPPC with hyperventilation or secretagogues. *Am J Physiol Lung Cell Mol Physiol*. 2003;284(5):L759-65
- [57] [Quintero OA](#), [Korfhagen TR](#), [Wright JR](#). Surfactant protein A regulates surfactant phospholipid clearance after LPS-induced injury in vivo. *Am J Physiol Lung Cell Mol Physiol*. 2002;283(1):L76-85

- [58] [Meschi J, Crouch EC, Skolnik P, Yahya K, Holmskov U, Leth-Larsen R, Tornoe I, Tecele T, White MR, Hartshorn KL.](#) Surfactant protein D binds to human immunodeficiency virus (HIV) envelope protein gp120 and inhibits HIV replication. *J Gen Virol.* 2005;86:3097-107
- [59] [Botas C, Poulain F, Akiyama J, Brown C, Allen L, Goerke J, Clements J, Carlson E, Gillespie AM, Epstein C, Hawgood S.](#) Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. *Proc Natl Acad Sci USA.* 1998;29:95:11869-74
- [60] [van Iwaarden JF, van Strijp JA, Ebskamp MJ, Welmers AC, Verhoef J, van Golde LM.](#) Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages. *Am J Physiol.* 1991;261:L204-9
- [61] [Ghildyal R, Hartley C, Varrasso A, Meanger J, Voelker DR, Anders EM, Mills J.](#) Surfactant protein A binds to the usion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity. *J Infect Dis.* 1999;180(6):2009-13
- [62] [Stamme C, Muller M, Hamann L, Gutschmann T, Seydel U.](#) Surfactant protein a inhibits lipopolysaccharide-induced immune cell activation by preventing the interaction of lipopolysaccharide with lipopolysaccharide-binding protein. *Am J Respir Cell Mol Biol.* 2002;27(3):353-60

- [63] [Barr FE, Pedigo H, Johnson TR, Shepherd VL.](#) Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages. Am J Respir Cell Mol Biol. 2000;23(5):586-92
- [64] [Ikegami M, Weaver TE, Conkright JJ, Sly PD, Ross GF, Whitsett JA, Glasser SW.](#) Deficiency of SP-B reveals protective role of SP-C during oxygen lung injury. J Appl Physiol. 2002 Feb;92(2):519-26
- [65] [Vaccaro AM, Salvioli R, Tatti M, Ciaffoni F.](#) Saposins and their interaction with lipids. Neurochem Res. 1999;24(2):307-14
- [66] [Wissel H, Looman AC, Fritzsche I, Ruestow B, Stevens PA.](#) SP-A-binding protein BP55 is involved in surfactant endocytosis by type II pneumocytes. Am J Physiol. 1996;271:L432-40
- [67] [Wissel H, Zastrow S, Richter E, Stevens PA.](#) Internalized SP-A and lipid are differentially resecreted by type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 2000;278(3):L580-90
- [68] [Stevens PA, Wissel H, Zastrow S, Sieger D, Zimmer KP.](#) Surfactant protein A and lipid are internalized via the coated-pit pathway by type II pneumocytes.

Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L141-51

- [69] [Wissel H, Lehfeldt A, Klein P, Muller T, Stevens PA.](#) Endocytosed SP-A and surfactant lipids are sorted to different organelles in rat type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 2001;281(2):L345-60
- [70] Maass M, Harig U. Evaluation of Culture Conditions Used for Isolation of Chlamydia pneumoniae, Am J Clin Pathol 1995; 103:141-141
- [71] Maaß M, Zellkultur für Chlamydia pneumoniae, Arbeitsanweisung im Arbeitsbereich: Molekulare Diagnostik Genlabor I, Institut für Med. Mikrobiologie und Hygiene Universität zu Lübeck, 1999
- [72] Dobbs RG, Gonzalez R and Williams MC. An improved method for isolating type II cells with high yield and purity. Am Rev Respir Dis 1986;134: 141-145
- [73] Chander A, Claypool WD Jr, Strauss JF 3rd, Fisher AB. Uptake of liposomal phosphatidylcholine by granular pneumocytes in primary culture. Am J Physiol. 1983;245(5 Pt 1):C397-404
- [74] Hawgood S, Efrati H, Schilling J, Benson BJ. Chemical characterization of lung surfactant apoproteins: amino acid composition, N- terminal sequence and enzymic digestion. Biochem Society Transactions 1985;13.1092-1096
- [75] Bradford MM. A Rapid and Sensitive Method for the Quantitation of

Microgram Quantities of Protein Utilizing the Principles of Protein-Dye Binding,
Analyt. Biochem 1976; 72: 248 - 254

- [76] Wright, JR, Immunomodulatory functions of surfactant, *Physiol Rev*
77:931-962, 1997
- [77] [Wright JR, Clements JA](#). Metabolism and turnover of lung surfactant.
Am Rev Respir Dis 1987;136(2):426-44
- [78] [Shannon JM, Jennings SD, Nielsen LD](#). Modulation of alveolar type II cell
differentiated function in vitro.
Am J Physiol. 1992;262:L427-36
- [79] [Wissel H, Schulz C, Rudiger M, Krull M, Stevens PA, Wauer R](#).
Chlamydia pneumoniae affect surfactant trafficking and secretion due to changes
of type II cell cytoskeleton. *Am J Respir Cell Mol Biol*. 2003;29:303-13
- [80] Taraska T, Ward ME, Ajioka RS, Wyrick PB, Davis-Kaplan SR, Davis CH,
Kaplan J. The late chlamydial inclusion membrane is not derived from the
endocytic pathway and is relatively deficient in host proteins. *Infect Immun* 1996;
64:3713- 3727
- [81] AL-Younes HM, Rudel T, Meyer TF. Characterization and intracellular
trafficking pattern of vacuoles containing *Chlamydia pneumoniae* in human
epithelial cells. *Cell Microbiol* 1999; 1:237-247

- [82] Finlay BB and Cossart, P. Exploitation of mammalian host cell functions by bacterial pathogens. *Science*. 1976;276:718-725
- [83] [Belland RJ, Zhong G, Crane DD](#), Hogan D, Sturdevant D, Sharma J, Beatty WL, Caldwell HD. Genomic transcriptional profiling of the developmental cycle of *Chlamydia trachomatis*. *Proc Natl Acad Sci U S A*. 2003; 8:100:8478-83
- [84] Carabeo RA, Griesbacher SS, Fischer E, Hackstadt T. *Chlamydia trachomatis* induces remodeling of the actin cytoskeleton during attachment and entry into HeLa cells. *Infect. Immun*. 2002;70: 3793-3803
- [85] Coombes BK and Mahony JB. Identification of MEK- and phosphoinositide 3-kinase-dependent signaling as essential events during *Chlamydia pneumoniae* invasion of Hep2 cells. *Cell. Microbiol*. 2002;4: 447-460
- [86] [Rose M, Lindberg DA](#). Effect of pulmonary pathogens on surfactant. *Dis Chest*. 1968;53(5):541-4
- [87] [Singh TK, Abonyo B, Narasaraju TA, Liu L](#). Reorganization of cytoskeleton during surfactant secretion in lung type II cells: a role of annexin II. *Cell Signal*. 2004;16:63-70
- [88] Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J. Decreased surfactant protein A in patients with bacterial pneumonia. *Am Rev Respir Dis* 1993;147:653-657

- [89] Gunther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumoniae, acute respiratory distress syndrome, and cardiogenic lung edema. *Am J Respir Crit Care Med* 1996, 153:176-184
- [90] [Rupp J, Droemann D, Goldmann T, Zabel P, Solbach W, Vollmer E, Branscheid D, Dalhoff K, Maass M.](#) Alveolar epithelial cells type II are major target cells for *C. pneumoniae* in chronic but not in acute respiratory infection. *FEMS Immunol Med Microbiol.* 2004;1:41(3):197-203
- [91] Seoung-Ju P, Yong CL, Yang KR, Seroprevalence of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in Stable Asthma and Chronic Obstructive Pulmonary Disease. *J Kor Med Sci* 2005;20:225-228
- [92] [Schmidt SM, Muller CE, Gurtler L, Bruns R, Ballke EH, Wiersbitzky H, Ehlers M, Rose HJ, Wiersbitzky SH.](#) *Chlamydia pneumoniae* respiratory tract infection aggravates therapy refractory bronchitis or pneumonia in childhood. *Klin Padiatr* 2005;217:9-14
- [93] Oberley RE, Ault KA, Neff TL, Khubchandani KR, Crouch EC, Snyder JM. Surfactant proteins A and D enhance the phagocytosis of *Chlamydia* into THP-1 cells. *Am J Physiol Lung Cell Mol Physiol* 2004;287:L296-306

- [94] Shemer-Avni Y, Liebermann D. Chlamydia pneumoniae- Induces Ciliostasis in Ciliated Bronchial Epithelial Cells. *J Infect Dis* 1995;171:1274-8
- [95] Yamaguchi H, Haranaga S, Widen R, Friedman H, Yamamoto Y. Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages. *Infect Immun.* 2002 May;70:2392-8
- [96] Redecke V, Dahlhoff K, Bohnet S, Braun J, Maass M. Interaction of Chlamydia pneumoniae and Human Alveolar Macrophages: Infection and Inflammatory Response. *Am J Resp Cell Mol Biol* 1998;19:721-727
- [97] Wissel H, Schulz C, Koehne P, Richter E, Maass M, Rudiger M. Chlamydia pneumoniae induces expression of toll-like receptor 4 and release of TNF-alpha and MIP-2 via an NF-kappaB pathway in rat type II pneumocytes. *Respir Res* 2005; 3:6(1):